Milk Thistle Liver Wellness Randomized Trial: What the Evidence Says

Quick Answer

Milk Thistle Liver Wellness Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Nonalcoholic fatty liver disease (NAFLD), also known as metabolic associated fatty liver disease (MAFLD), is the most common chronic liver disease with a prevalence of almost 25% worldwide and 31.8% in all adults in the Middle East and North Africa regions. [Shaker Mohamed Kamal (2025); evidence level 2]
• The etiology of NASH has been linked to several risk factors, such as body obesity, insulin resistance, and oxidative stress. [Shaker Mohamed Kamal (2025); evidence level 2]
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its progressive form, Metabolic Dysfunction-Associated Steatohepatitis (MASH), are two increasingly common liver diseases caused by a combination of genetic, metabolic, and lifestyle factors. [Vrentzos Emmanouil (2025); evidence level 4]
• This review focuses mainly on studies published in the last ten years, providing an up-to-date synthesis of evidence regarding nutraceuticals in MASLD. [Vrentzos Emmanouil (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For milk thistle liver wellness randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Shaker Mohamed Kamal (2025). The activity of a herbal medicinal product of Phyllanthus niruri and Silybum marianum powdered extracts (Heptex®) in patients with apparent risk factors for nonalcoholic steatohepatitis: a phase II, multicentered, randomized, double-blind, placebo-controlled clinical trial. DOI: 10.1186/s12906-024-04692-y. PMCID: PMC11715200. PMID: 39789561. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC11715200/
• Vrentzos Emmanouil (2025). Nutraceutical Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Path to Liver Health. DOI: 10.3390/nu17101657. PMCID: PMC12113997. PMID: 40431398. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12113997/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.